ISABELA
A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
What will happen during the trial?
This is a phase II study of isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. Approximately 50 participants will take part in this research study. The primary objective is determining the overall response rate of the treatment. Treatment is until progression, adverse events, or withdrawal of consent.
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 50 patients (estimated)
- Sponsors
- Massachusetts General Hospital
- Collaborators
- Sanofi, GlaxoSmithKline
- Tags
- Monoclonal Antibody, CD38, Quadruplet Therapy
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1728
- NCT Identifier
- NCT05922501
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.